Invetx
Latest round
- Series B
Last raised
- Mar 2022
Total raised
- $81M
Investors
- 9
About Invetx
Founded in 2018 in Boston, US, Invetx, Inc. is engaged in the development of biopharmaceutical solutions for pets.Invetx focuses on developing biopharmaceutical products that cater to the health of dogs and cats, specifically targeting chronic conditions such as osteoarthritis, allergies, cancer, and diabetes. They have developed a Half-Life Extension Technology Platform, aimed at prolonging the efficacy of monoclonal antibody treatments, thereby enhancing veterinary care.Invetx generates revenue through direct sales to veterinary clinics and strategic partnerships with animal hospitals and pet owners.Following the recent acquisition agreement with Dechra Pharmaceuticals PLC, effective July 2024, Invetx will leverage this partnership to enhance its offerings in drug treatments and compliance services for pets. The acquisition will facilitate the development and launch of new products aimed at addressing unmet needs in veterinary medicine. Additionally, Invetx plans to expand its market presence internationally, targeting regions with growing demands for veterinary biotherapeutics.
Who invested in Invetx
9 investors across 3 rounds
See all investors in Invetx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Invetx
Who invested in Invetx?
Invetx has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Invetx raised?
Invetx has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Invetx last raise money?
Invetx's most recent round on record is a Series B, in Mar 2022.
What does Invetx do?
Founded in 2018 in Boston, US, Invetx, Inc.
Where is Invetx headquartered?
Invetx is headquartered in Boston, US.
Which VCs invest in companies like Invetx?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Invetx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Invetx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.